HUTCHMED (NASDAQ:HCM) Posts Quarterly Earnings Results, Misses Expectations By $2.49 EPS

HUTCHMED (NASDAQ:HCM) posted its earnings results on Thursday. The company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $2.50 by ($2.49), reports. The company had revenue of $135.42 million for the quarter, compared to the consensus estimate of $290.50 million.

Here are the key takeaways from HUTCHMED’s conference call:

• FRUZAQLA delivered strong ex-China momentum with 26% growth and $366 million in in-market sales across >38 countries, providing a clear international growth driver despite U.S. Medicare Part D headwinds.
• China commercial sales recovered in H2 (21% H2 growth for ELUNATE), with NRDL renewal at no price cut and new indication/regulatory filings (RCC) supporting the company’s 2026 oncology revenue guidance of $330M–$450M.
• Balance sheet strength — roughly $1.4 billion cash — positions HUTCHMED to accelerate global development of its ATTC platform and pursue selective in‑licensing/M&A or partnerships to validate and scale the program.
• Pipeline catalysts ahead — two ATTC candidates (HMPL‑A251 and HMPL‑A580) are in global Phase I, A251 targets HER2‑expressing tumors with a reported bystander effect, and multiple near‑term readouts/NDA opportunities (SAFFRON, SANOVO, savolitinib gastric, Sovleplenib ITP) could materially re‑rate the story.
• Certain China products (ORPATHYS, Surufatinib) showed soft performance due to fierce competition and emerging PRRT/nuclear medicine entrants, and earlier China sales were pressured by salesforce restructuring after a GC indication setback — risks to near‑term commercial momentum remain.

HUTCHMED Price Performance

HCM opened at $13.85 on Friday. The company’s 50-day moving average is $14.71 and its 200 day moving average is $14.97. HUTCHMED has a fifty-two week low of $11.51 and a fifty-two week high of $19.50. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.65 and a quick ratio of 4.51.

Institutional Trading of HUTCHMED

A number of hedge funds have recently bought and sold shares of the company. State Street Corp grew its position in HUTCHMED by 1.2% during the fourth quarter. State Street Corp now owns 321,305 shares of the company’s stock valued at $4,283,000 after acquiring an additional 3,801 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of HUTCHMED by 3.0% in the 4th quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock worth $1,798,000 after acquiring an additional 3,900 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of HUTCHMED by 157.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 55,969 shares of the company’s stock valued at $746,000 after purchasing an additional 34,248 shares in the last quarter. M&G PLC grew its holdings in shares of HUTCHMED by 26.7% during the 4th quarter. M&G PLC now owns 259,033 shares of the company’s stock valued at $3,367,000 after purchasing an additional 54,601 shares during the last quarter. Finally, XY Capital Ltd grew its holdings in shares of HUTCHMED by 9.2% during the 4th quarter. XY Capital Ltd now owns 57,610 shares of the company’s stock valued at $768,000 after purchasing an additional 4,853 shares during the last quarter. Institutional investors own 8.82% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on HCM shares. Weiss Ratings reissued a “hold (c)” rating on shares of HUTCHMED in a report on Thursday, January 22nd. Wall Street Zen lowered HUTCHMED from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Jefferies Financial Group raised HUTCHMED to a “strong-buy” rating in a research report on Monday, January 19th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $20.88.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.